Cargando…
HBV and HCV Therapy
One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Followin...
Autores principales: | Lampertico, Pietro, Aghemo, Alessio, Viganò, Mauro, Colombo, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185503/ https://www.ncbi.nlm.nih.gov/pubmed/21994557 http://dx.doi.org/10.3390/v1030484 |
Ejemplares similares
-
The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent
por: D’Ambrosio, Roberta, et al.
Publicado: (2014) -
Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B
por: Viganò, Mauro, et al.
Publicado: (2012) -
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022) -
Therapeutic vaccines in HBV: lessons from HCV
por: Barnes, Eleanor
Publicado: (2015) -
Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
por: D’Ambrosio, Roberta, et al.
Publicado: (2021)